Key takeaways

  • The over 4% yield is a indicated, trailing figure as at mid-2026, not a forecast.
  • EZZ has lifted its dividend most years since first paying in 2021, all fully franked.
  • FY2025 was solid, but the first half of FY2026 fell to a maiden loss.

A health-supplements group paying a rising, fully franked dividend and an 8%-plus yield looks like a rare growth-and-income combination. EZZ Life Science (ASX: EZZ) built exactly that reputation over four years of steady payouts.

The story has become more complicated. A sharp fall in first-half FY2026 sales and the company’s first loss since listing raise a pointed question: can the payout keep pace if the growth stalls? This article weighs the record against the recent wobble.

 

Company overview and business model

EZZ Life Science (ASX: EZZ) is an Australian health and wellness company that develops, markets and distributes branded health supplements. Its range spans genomic and longevity products, immunity, gut health and skincare, across dozens of active product lines. A secondary business distributes the EAORON skincare brand in Australia and New Zealand.

The group’s growth engine has been China, where it sells through cross-border e-commerce platforms including Douyin and Kuaishou. In FY2025, China accounted for around 66% of revenue, with South-East Asia near 21% and Australia and New Zealand around 13%. EZZ listed on the ASX in January 2021 and remains a small-cap, with a share price in the region of A$0.50 as at mid-2026 (a figure that could not be precisely verified at the time of writing).

Competitors include other supplement and wellness brands selling into the same Asian e-commerce channels.

 

Understanding the over 4% indicated yield

EZZ paid around 4 cents per share over the year (two half-yearly dividends of about 2 cents each), and against a share price that has pulled back from its highs, that produces a high single-digit indicated yield.

The special-situation caveat is the recent earnings reversal. A trailing yield uses past dividends; if the business has just turned loss-making, the same payout may not be repeated. The high yield partly reflects a falling share price, which is itself a signal of concern about the growth outlook.

 

Earnings, revenue and free cash flow

FY2025 (to June 2025) was broadly steady: revenue was around A$66.9 million, essentially flat on the prior year’s A$66.4 million, and net profit was about A$6.73 million on strong gross margins near 74%.

The first half of FY2026 was the turning point. Revenue fell about 18% to roughly A$24.8 million, and the company reported a net loss of around A$641,000 — its first since listing — as normalised earnings compressed sharply. Operating cash flow also turned negative in the period. For a company whose dividend had been comfortably covered, this is a material change.

 

Dividend coverage and payout ratio

On the FY2025 result, the payout ratio sat around 64–67% of earnings — a reasonable, sustainable-looking level for a growing company. That is the reassuring part of the history.

The concern is forward cover. With the first half of FY2026 loss-making, current-period earnings do not cover the dividend at all. If the second half does not recover strongly, the company would be paying from reserves rather than profit, which changes the sustainability picture quickly.

 

Balance sheet, debt and liquidity

EZZ’s balance sheet is a genuine strength. The company carries no external debt and held around A$9.96 million in cash at 31 March 2026, with net tangible assets reported near A$0.59 per share.

That debt-free position and cash buffer give the board room to maintain the dividend through a soft patch. But cash was being drawn down as operating cash flow turned negative, so the buffer should not be treated as limitless if trading stays weak.

 

Industry outlook and growth drivers

Demand for supplements, longevity and wellness products remains a structural growth theme, particularly among Asian consumers. EZZ’s success has come from riding that demand through Chinese social-commerce platforms, and new product launches and category expansion are the main growth levers.

The flip side is dependence on those same channels. Chinese consumer sentiment, platform algorithm changes, competition and regulation of cross-border e-commerce can all move EZZ’s sales quickly — as the first-half FY2026 decline showed.

 

Key risks to the dividend

  • Heavy reliance on China, where sales recently fell sharply.
  • A swing to a first-half loss, removing near-term earnings cover.
  • Negative operating cash flow drawing down the cash balance.
  • Platform, competition and regulatory risk in cross-border e-commerce.
  • A short dividend history, offering limited evidence of resilience in a downturn.

 

Bull case

EZZ has a proven, high-margin brand model, a four-year record of rising fully franked dividends, no debt and a solid cash balance. If the first-half stumble proves temporary and Chinese demand re-accelerates on new products, earnings and the dividend could resume their upward path, making the current yield look attractive.

 

Bear case

A first loss since listing, an 18% sales fall and negative operating cash flow are a worrying cluster for a stock whose appeal rested on growth. If China stays soft, the dividend could be trimmed, and a small-cap dependent on discretionary consumer spending can de-rate quickly.

 

Catalysts to watch

  • The FY2026 full-year result and whether the second half recovers.
  • Chinese consumer demand and cross-border e-commerce trends.
  • New product launches and category expansion updates.
  • Any change to the dividend policy or payout level.
  • Movements in cash and operating cash flow.

 

Conclusion

EZZ Life Science (ASX: EZZ) offers a rare mix of a growth story and a rising, fully franked dividend, with a screener yield near over 4%. The track record is genuinely good, and the balance sheet is clean — but a maiden first-half loss and falling China sales mean the next dividend is no longer a formality. EZZ may appeal to investors comfortable with consumer and China risk, yet the dividend is not guaranteed and could be reduced, suspended or cancelled.